Trials / Completed
CompletedNCT05320016
Effects of Remimazolam on Quality of Recovery After Ambulatory Surgery
Effects of Remimazolam Combined With Remifentanil on Quality of Recovery After Ambulatory Hysteroscopic Surgery: a Prospective, Observational Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 38 (actual)
- Sponsor
- Seoul National University Bundang Hospital · Academic / Other
- Sex
- Female
- Age
- 19 Years – 75 Years
- Healthy volunteers
- —
Summary
Remimazolam is a novel ultra-short acting benzodiazepine with rapid onset of effects, short maintenance and faster recovery time. Due to its recent development, few studies have investigated the effect of remimazolam on postoperative recovery mainly focusing on physiologic endpoints, recovery time and possible adverse events. Although these parameters are crucial and need evaluation, the investigators ignore quality of recovery from participant's perspective. For this purpose, various measurment tools have been developed for psychometric evaluation of QoR score.
Detailed description
To date, there has not been a study investigating the impact of remimazolam on quality of recovery (QoR). This study evaluates the effect of remimazolam on QoR of participants undergoing general anesthesia using remimazolam-remifentanil total intravenous anesthesia (TIVA) for hysteroscopy as day surgery basis. Herein, the investigators used the translated Korean version of the 15-item Quality of Recovery-15 (QoR-15K) questionnaire, which was previously validated in Korean surgical participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Remimazolam | Effects of remimazolam on quality of recovery scores after ambulatory hysteroscopic surgery |
Timeline
- Start date
- 2021-11-01
- Primary completion
- 2021-12-31
- Completion
- 2021-12-31
- First posted
- 2022-04-11
- Last updated
- 2022-04-11
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05320016. Inclusion in this directory is not an endorsement.